 NEW YORK, Jan. 11, 2021 GLOBE NEWSWIRE -- Intercept Pharmaceuticals, Inc. Nasdaq:ICPT, a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced the appointment of Jared M. Freedberg as General Counsel and Secretary. Mr. Freedberg joins Intercept from Immunomedics, Inc., which was acquired by Gilead Sciences in October of 2020. 